Intensive lifestyle modification

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92

Higher baseline adiponectin was more strongly associated with lower incident diabetes risk in the lifestyle group than in the placebo group, and this association persisted after full adjustment for ba

Effect: improvement; HR 0.69; CI: 95% CI 0.52, 0.92